Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB2 | P07550 | 9/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.36 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | EPHX2 | P34913 | 3/20 | 0.33 |
| ▸ | PPARG | P37231 | 3/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3308130 | 1.00 | ADRB2 (0.42) | ADRB2POLBNOTUMFOLH1LMNA | |
| SCHEMBL3306655 | 0.93 | FOLH1 (0.37) | ADRB2POLBFOLH1EPHX2PPARG | |
| SCHEMBL3306650 | 0.93 | FOLH1 (0.37) | ADRB2POLBFOLH1EPHX2PPARG | |
| SCHEMBL3309680 | 0.87 | ADRB2 (0.43) | ADRB2FOLH1LMNAMAPTPPARG | |
| SCHEMBL3309683 | 0.87 | ADRB2 (0.43) | ADRB2FOLH1LMNAMAPTPPARG | |
| SCHEMBL4461700 | 0.86 | CPA1 (0.45) | ADRB2FOLH1 | |
| SCHEMBL4478582 | 0.86 | CPA1 (0.45) | ADRB2FOLH1 | |
| SCHEMBL4510891 | 0.83 | POLB (0.37) | POLBFOLH1MAPT | |
| SCHEMBL4510897 | 0.83 | POLB (0.37) | POLBFOLH1MAPT | |
| SCHEMBL4609155 | 0.79 | POLB (0.41) | POLBFOLH1PPARG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100113411-A1 | Selected CGRP antagonists, processes for preparing them and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2010-05-06 | — | — | US | disclosed |
| CN-1708493-A | Selected CGRP antagonists, method for production and use thereof as medicament | BOEHRINGER INGELHEIM PHARMA (DE) | 2005-12-14 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100113411-A1 | Selected CGRP antagonists, processes for preparing them and their use as pharmaceutical compositions | CALCRL, CALCR, CALCA | ADRB2 63/4885POLB 2618/4885NOTUM 3740/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.